Bortecad Bortezomib 2 Mg Injection

Bortecad Bortezomib 2 Mg Injection Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Packaging Type
Vial

Pacakaging (Quantity Per Box)
1 vial per box

Dosage Form
Injection

Salt Composition
Bortezomib

Life Span
24 months

Origin of Medicine
India

Brand Name
Bortecad

Drug Type
Allopathic

Ingredients
Bortezomib

Function
Anti-cancer agent

Recommended For
Cancer patients

Dosage
2 mg

Dosage Guidelines
As directed by physician

Suitable For
Adults

Quantity
1 Vial

Storage Instructions
Store below 25C

Injection Route
IV/Subcutaneous

Prescription Required
Yes

Colour
White to off-white

Single-use
Yes

Reconstitution
Required

Administration
By healthcare professional

Formulation
Lyophilized powder

Antineoplastic Category
Proteasome inhibitor

Hospital/Clinical Use
Yes

Bortecad Bortezomib 2 Mg Injection Trade Information

Minimum Order Quantity
1 Piece

Supply Ability
5000 Pieces Per Month

Delivery Time
7 Days

About Bortecad Bortezomib 2 Mg Injection

Step into the world of valorous innovation with Bortecad Bortezomib 2 Mg Injection. Crafted in India, this noteworthy anti-cancer agent is a single-use, lyophilized powder presented in a fresh, white to off-white vial. Featuring the virtuoso proteasome inhibitor, Bortezomib, it's tailored for intravenous or subcutaneous administration by healthcare professionals. Suitable for adults tackling multiple myeloma or mantle cell lymphoma, this potent remedy requires prescription and reconstitution, with stringent storage instructions below 25C. Grab this validated hospital-grade formulation and try now for advanced cancer care.

Effective Cancer Treatment for Clinical Precision

Bortecad Bortezomib 2 Mg Injection is meticulously formulated for clinical application on adult patients. Its expertise surfaces in managing multiple myeloma and mantle cell lymphoma through a reliable, single-use lyophilized powder. Administered exclusively by healthcare professionals, this medication assures optimal absorption via intravenous or subcutaneous injection. With its precise application, trusted material integrity, and professional oversight, Bortecad upholds exemplary performance for noteworthy therapeutic interventions.

Robust Global Supply with Trusted Certifications

Bortecad Bortezomib 2 Mg Injection is stock ready for prompt handover to hospitals and clinics worldwide. Our supply chain meets vigorous international export market standards, with robust supply ability tailored for global demand. Each product is backed by essential certifications, verifying the highest manufacturing and safety benchmarks. As an exporter, supplier, trader, and wholesaler from India, we ensure every vial is delivered with unmatched reliability and traceability.

FAQ's of Bortecad Bortezomib 2 Mg Injection:

Q: How is Bortecad Bortezomib 2 Mg Injection administered?

A: Bortecad Bortezomib 2 Mg Injection is administered by a healthcare professional either intravenously (IV) or subcutaneously after proper reconstitution as per the physician's guidance.

Q: What specific conditions does this injection treat?

A: This injection is recommended for adults with multiple myeloma or mantle cell lymphoma and is indicated as an anti-cancer agent under the proteasome inhibitor category.

Q: When should Bortecad Bortezomib 2 Mg Injection be used?

A: It should be used strictly on a healthcare professional's recommendation, following a physician's prescribed dosage and schedule tailored to the patient's medical needs.

Q: Where should this medication be stored for optimum freshness?

A: Bortecad Bortezomib 2 Mg Injection must be stored below 25C to maintain its stability and effectiveness until administration.

Q: What is the process for reconstituting the lyophilized powder?

A: The lyophilized powder should be reconstituted with a sterile solvent according to the detailed instructions provided in the vial's packaging and handled exclusively by medical staff.

Q: What are the benefits of choosing Bortecad Bortezomib 2 Mg Injection?

A: Choosing Bortecad ensures cancer patients receive a fresh, single-use, hospital-grade medication produced under noteworthy safety certifications, tailored for effective clinical outcomes in challenging oncological cases.

Tell us about your requirement